1.
Clin Microbiol Infect
; 27(9): 1360-1361, 2021 09.
Article
in English
| MEDLINE
| ID: mdl-33957274
Subject(s)
Drug Resistance, Bacterial , Escherichia coli Infections , Escherichia coli , Fosfomycin , Urinary Tract Infections , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Australia/epidemiology , Escherichia coli/drug effects , Escherichia coli/genetics , Escherichia coli Infections/drug therapy , Escherichia coli Infections/epidemiology , Fosfomycin/pharmacology , Humans , Microbial Sensitivity Tests , Urinary Tract Infections/drug therapy , Urinary Tract Infections/epidemiology , beta-Lactamases
2.
Int J Antimicrob Agents
; 56(4): 106121, 2020 Oct.
Article
in English
| MEDLINE
| ID: mdl-32739475
ABSTRACT
Of 1033 Escherichia coli urinary tract infection isolates collected from females >12 years of age in Australia in 2019, only 2 isolates were resistant to fosfomycin with a minimum inhibitory concentration (MIC) of >256 mg/L. Despite having different multilocus sequence types, the two isolates harboured an identical plasmid-encoded fosA4 gene. The fosA4 gene has previously been identified in a single clinical E. coli isolate cultured in Japan in 2014. Each fosfomycin-resistant isolate harboured two conjugative plasmids that possessed an array of genes conferring resistance to aminoglycosides, ß-lactams, macrolides, quinolones, sulfonamides and/or trimethoprim.